Abbott Raises Stake in Ibis Biosciences by $20M; Retains Right to Buy | GenomeWeb
NEW YORK (GenomeWeb News) – Abbott has invested a second $20 million in pathogen detection developer Ibis Biosciences, upping its stake in the company to 18.6 percent, Ibis parent firm Isis Pharmaceuticals said today.
The agreement follows a $20 million investment that Abbott made in January that gave it a 10.25 percent stake in the firm.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.